Abstract
Congestive heart failure is an increasingly important cause of cardiovascular
morbidity and mortality. It is the number one cause of hospitalization among
individuals aged 65 and over. The United States Medicare system pays out more
for the care of congestive heart failure than it does for all forms of cancer
combined. While this is a challenge for the US healthcare system, it indicates
a strong market opportunity for pharmaceutical companies involved in CHF
treatment.
Kalorama Information' s Congestive Heart Failure, Major World Markets series
looks at CHF treatment. Volume I of this series looks at Pharmaceutical
Treatments in the following key categories which are used to treat this
disease:
- ACEIs/ARBs
- Beta-Blockers
- Diuretics
- Inotropes
- Vasodilators
- Aldosterone Inhibitors
This Kalorama Information report includes current market, market forecasts,
product discussion and pipeline analysis are included for each segement of
this report. General trends in this important disease category are also
included. Relevant companies in the industry are profiled. This report is the
result of Dr. Kenneth Krul' s exhaustive analysis and primary research with key
executives in the industry.
- Abbott Laboratories
- Actelion Pharmaceuticals US
- Aldagen
- Alexion Pharmaceuticals
- AstraZeneca LP
- Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
- Bristol-Myers Squibb
- CardioVascular Biotherapeutics
- CoGenesys, Inc.
- Encysive Pharmaceuticals
- GlaxoSmithKline (US)
- Inotek Pharmaceuticals
- Mylan Pharmaceuticals
- Novartis Pharmaceutical Corp.
- Pfizer, Inc.
- Roche Pharmaceuticals
- Sanofi-Aventis (US)
- Scios, Inc.
- Vasogen, Inc.
- Zealand Pharma
| 
View Cart
